Evidence map›Paper›PMID 40576343›Full record

ArticlemBio2025

A split ALFA tag-nanobody system for protein localization and proximity proteomics in mycobacteria.

Allison Fay, Andrew P Kurland, Zhuoning Li, Mara Monetti, Jeffrey R Johnson, Michael S Glickman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Nanobodies in animal infectious disease control: diagnosis and therapy.Frontiers in cellular and infection microbiology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Allison FayImmunology Program, Sloan-Kettering Institute, New York, New York, USA.ORCID 0000-0001-5957-5376
Andrew P KurlandDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Zhuoning LiProteomics Innovation Laboratory, Sloan Kettering Institute Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Mara MonettiProteomics Innovation Laboratory, Sloan Kettering Institute Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jeffrey R JohnsonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-4221-298X
Michael S GlickmanImmunology Program, Sloan-Kettering Institute, New York, New York, USA.ORCID 0000-0001-7918-5164

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tri-Institutional Tuberculosis Research Advancement Center (TRAC)P30AI168433 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Daniel W Fitzgerald, Kyu Y Rhee · 2022 to 2026
$5.8M
NCI NIH HHS P30 CA008748NIAID NIH HHS P30 AI168433
6 · The paper itself

Abstract

Tuberculosis remains a globally significant infection, and new insights into the biology of IMPORTANCE: This study establishes a new platform for discovery proteomics in mycobacteria using a new nanobody-based approach. The findings will be of interest for all bacteriologists as the approach will be applicable to a variety of microbial systems.

Indexed as

Bacterial ProteinsMycobacterium tuberculosisProteomicsSingle-Domain AntibodiesProtein TransportRecombinant Fusion ProteinsBacterial ProteinsRecombinant Fusion ProteinsSingle-Domain AntibodiesMycobacteriumMycobacterium tuberculosisprotein-protein interactionsproteomics

Identifiers

PMID40576343
PMCPMC12345155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.